Illumination of the complement receptors C3aR and C5aR signaling by anaphylatoxins

Yue Wang, Weiyi Liu, Youwei Xu, Qingning Yuan, Xinheng He, Ping Luo, Wenjia Fan, Jinpeng Zhu, Xinyue Zhang, Xi Cheng, Yi Jiang, H. Eric Xu, Youwen ZhuangbioRxiv 2023 · DOI

TL;DR

This paper presents the high-resolution cryo-EM structures of complement receptors C3aR and C5aR1, both in their apo states and bound to their respective ligands, C3a and C5a. These structures reveal novel insights into how these receptors recognize and are activated by anaphylatoxins, offering crucial templates for developing new anti-inflammatory drugs.

What Problem Does This Paper Address?

The complement system is a critical part of our immune defense, but its dysregulation can lead to various inflammatory disorders like sepsis and asthma. Two key players in this system are the anaphylatoxins C3a and C5a, which signal through their receptors C3aR and C5aR1. While we know these receptors are important, the precise molecular mechanisms by which endogenous C3a and C5a bind to and activate their receptors have remained largely elusive. This lack of detailed structural understanding has hindered the development of targeted therapies for inflammatory diseases.

Methods

The researchers employed cryo-electron microscopy (cryo-EM) to determine the structures of the C3aR-Gi and C5aR1-Gi complexes. This involved:

  • Recombinant protein expression: Producing C3a, C5a, C3aR, and C5aR1 in insect cells.
  • Complex assembly: Co-expressing the receptors with Gi heterotrimers to mimic cellular signaling.
  • Cryo-EM data collection: Capturing high-resolution images of the protein complexes.
  • 3D reconstruction: Using advanced computational algorithms (like RELION) to reconstruct the 3D structures from the 2D images.
  • Model building and refinement: Docking and manually adjusting protein models into the cryo-EM density maps.
  • Mutagenesis analysis: Systematically altering specific amino acids in the receptors and ligands to understand their role in binding and signaling.
  • Functional assays: Using GloSensor cAMP assays to measure receptor activation in response to ligands and mutants.

Datasets

The study did not introduce new benchmark datasets. Instead, it utilized existing knowledge and experimental data derived from:

  • Recombinant proteins: C3a, C5a, C3aR, C5aR1, and their mutants.
  • Gi heterotrimer: The intracellular signaling partner.
  • Antibody fragment (scFv16): Used to stabilize the complexes for cryo-EM.
  • Previous crystal structures: Used as starting points for model building (e.g., C3a PDB: 4HW5, C5a PDB: 5B4P, C5aR1-PMX53 PDB: 6C1R).

Key Insights and Ideas

  • Unique C-terminus Binding Mode: Unlike many other chemoattractant peptides that bind with their N-terminus, C3a and C5a engage their receptors with their C-termini. This is a fundamental difference that dictates how they interact.
  • Conserved Recognition Pattern: Despite differences in their sequences, C3a and C5a share a conserved recognition pattern within their respective binding pockets, particularly involving the last C-terminal arginine residue.
  • Ligand Selectivity: The distinct "pocket topologies" of C3aR and C5aR1 are crucial for mediating their specific binding to C3a and C5a, respectively.
  • Common Activation Mechanism: The structures suggest that C3aR and C5aR1 share a conserved mechanism for receptor activation, involving conformational changes in transmembrane helices.
  • N-terminal Loop's Role: The N-terminal loop of C5aR1, but not C3aR, plays a significant role in high-affinity binding to C5a, highlighting a receptor-specific interaction detail.

Key Results

  • High-Resolution Structures: The study successfully determined cryo-EM structures of apo-C3aR-Gi (3.2 Å), C3a-C3aR-Gi (2.9 Å), and C5a-C5aR1-Gi (3.0 Å) complexes.
  • Detailed Binding Interactions: The structures revealed specific polar and hydrophobic interactions between C3a/C5a and their receptors, identifying key residues involved in binding and activation.
  • Mutagenesis Confirms Structural Findings: Mutational studies on critical residues (e.g., R77 in C3a, R74 in C5a) confirmed their importance for receptor activation and ligand binding.
  • Functional Validation: cAMP assays demonstrated that the recombinant C3a and C5a were biologically functional and showed high selectivity for their respective receptors.
  • Drug Design Templates: The detailed structural information provides a solid foundation for designing small molecules that can selectively modulate C3aR and C5aR1 signaling for therapeutic purposes.

Limitations and Future Work

  • Flexible ECL2: The second extracellular loop (ECL2) of C3aR was largely unresolved, indicating its dynamic nature and potential role in ligand interaction or signaling. Further studies might be needed to fully characterize this region.
  • In Vitro System: The studies were conducted using purified proteins and cell-based assays. Future work could explore these interactions within a more complex cellular environment or in vivo.
  • Drug Development: While the structures provide templates, the actual development and testing of novel drugs targeting these receptors would be the next logical step. The authors suggest that these structures are crucial for "rational drug design."

Summary updated

Abstract

The complement receptors C3aR and C5aR, whose signaling are selectively activated by anaphylatoxins C3a and C5a, are important regulators of both innate and adaptive immune responses. Dysregulations of C3aR and C5aR signaling lead to multiple inflammatory disorders, including sepsis, asthma, and acute respiratory distress syndrome (ARDS). The mechanism underlying endogenous anaphylatoxin recognition and activation of C3aR and C5aR remains elusive. Here we reported the structures of C3a-bound C3aR and C5a-bound C5aR1 as well as an apo C3aR structure. These structures, combined with mutagenesis analysis, reveal a conserved recognition pattern of anaphylatoxins to the complement receptors that is different from chemokine receptors, unique pocket topologies of C3aR and C5aR1 that mediate ligand selectivity, and a common mechanism of receptor activation. These results provide crucial insights into the molecular understandings of C3aR and C5aR1 signaling and structural templates for rational drug design for treating inflammation disorders.
BibTeX
@misc{wang2023illumination,
  author = {Yue Wang and Weiyi Liu and Youwei Xu and Qingning Yuan and Xinheng He and Ping Luo and Wenjia Fan and Jinpeng Zhu and Xinyue Zhang and Xi Cheng and Yi Jiang and H. Eric Xu and Youwen Zhuang},
  title = {{Illumination of the complement receptors C3aR and C5aR signaling by anaphylatoxins}},
  year = {2023},
  doi = {10.1101/2023.01.18.524551},
  howpublished = {bioRxiv},
}
Figure